<?xml version='1.0' encoding='utf-8'?>
<document id="30554411"><sentence text="From Endogenous Compounds as Biomarkers to Plasma-Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics-Absorption, Distribution, Metabolism, Excretion-Drug-Drug Interaction Science Finally Arrived?" /><sentence text="It is now established that a drug's pharmacokinetics (PK) absorption, distribution, metabolism, excretion (ADME) and drug-drug interaction (DDI) profile can be modulated by age, disease, and genotype" /><sentence text=" In order to facilitate subject phenotyping and clinical DDI assessment, therefore, various endogenous compounds (in plasma and urine) have been pursued as drug-metabolizing enzyme and transporter biomarkers" /><sentence text=" Compared with biomarkers, however, the topic of circulating extracellular vesicles as &quot;liquid biopsy&quot; has received little attention within the ADME community; most organs secrete nanovesicles (e" /><sentence text="g" /><sentence text=", exosomes) into the blood that contain luminal &quot;cargo&quot; derived from the originating organ (proteins, messenger RNA, and microRNA)" /><sentence text=" As such, ADME profiling of plasma exosomes could be leveraged to better define genotype-phenotype relationships and the study of ontogeny, disease, and complex DDIs" /><sentence text=" If methods to support the isolation of tissue-derived plasma exosomes are successfully developed and validated, it is envisioned that they will be used jointly with genotyping, biomarkers, and modeling tools to greatly progress translational PK-ADME-DDI science" /><sentence text="" /></document>